Mr Mrs Miss Ms Dr Other

Mrs
Karen
Russell

Patent Director

Manchester Office

Life sciences

Telephone. +44(0) 161 247 4900
Email. [email protected]
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.
Vcard
Linkedin

Experience

Bringing over 20 years’ experience in private practice, Karen specialises in the fields of life sciences and pharmaceuticals. Having started her career in London, she joined HGF in 2010 and enjoys being an active member of the biotech and chemical teams in the Manchester office.

Karen’s experience covers a wide range of biotechnological and biopharmaceutical subject matter including nucleic acid and peptide based therapeutics. She has a particular interest in SPCs, and her practice includes filing and prosecution of SPC applications in both the medicinal and agrochemical fields.

In the course of her career, she has worked with a variety of clients, including universities, SMEs and large multi-nationals, providing guidance in patent prosecution before the EPO and internationally, as well as advice relating to patentability, freedom to operate, and SPC filings.

Karen holds an MA in Natural Sciences (Biological), and an MPhil in Biotechnology, both from the University of Cambridge. Her MPhil research investigated the genetic basis for the microbial degradation of cocaine.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

MA

Natural Sciences (Cantab)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Queen Mary and Westfield College Certificate in Intellectual Property Law

OTHER

MPhil Biotechnology (Cantab)

Publications

A Step Towards A Unitary SPC?

View publication online

EU SPC waiver for generic pharmaceuticals producers

View publication online

Related News

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

A leading case - beware sequence errors in patent claims

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Mr Justice Meade – 20 May 2025 The UK Patents Court has held that Samsung Bioepis’ and Amgen’s …

Read article

ICELAND left out in the cold by the General Court

Earlier in the month, the EU General Court issued its decision on Iceland Foods Ltd’s appeal of a decision of the Grand Board of Appeal of EUIPO to invalidate an …

Read article

HGF recognised in Managing IP’s New “Trusted Talent” Table in Germany

We are proud to announce that HGF has been ranked in Managing IP’s newly launched Trusted Talent table in Germany, a recognition of our ongoing commitment to excellence in intellectual …

Read article

Briefing Note: UKIPO SEP Consultation

Overview and Strategic Context The UKIPO’s 2025 consultation on Standard Essential Patents (SEPs), announced on 15 July 2025, signals a potential policy shift in how the UK approaches SEP licensing …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us